At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 361 enrolled
Drug / intervention
S5G4T-1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3 Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study of S5G4T-1 in the Treatment of Papulopustular Rosacea
In Brief
A Phase 3 clinical trial evaluating S5G4T-1 and S5G4T-2 for Papulopustular Rosacea. Completed, enrolled 361 participants across 1 site.
Detailed Summary
To assess the efficacy and safety of S5G4T-1 compared to its vehicle when applied once daily for 12 weeks in participants with papulopustular rosacea.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPapulopustular Rosacea
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedFeb 2018
Enrollment StartJun 2018
Primary CompletionMay 2019
TodayJul 2026
First PostedFeb 28, 2018
Enrollment StartJun 18, 2018
Primary CompletionMay 24, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 8.3 years ago
Interventions
S5G4T-1drug
Once a day topical cream
S5G4T-2drug
Once a day topical cream